AdipoGen Life Sciences

Retatrutide . sodium salt

CHF 65.00
In stock
AG-CP3-0044-M0011 mgCHF 65.00
AG-CP3-0044-M0055 mgCHF 260.00
AG-CP3-0044-M02525 mgCHF 980.00
AG-CP3-0044-M100100 mgCHF 2'000.00

BULK available!

Learn more about GLP-1 & GIP Receptor Agonists

More Information
Product Details
Synonyms LY3437943; GGG Tri-agonist
Product Type Chemical

C221H342N46O68 . Na

MW 4731.4 . 23.0


CAS 2381089-83-2 (free acid)
Source/Host Chemicals Synthetic.
Purity Chemicals ≥98% (HPLC)
Appearance White lyophilized powder.
Solubility Soluble in water (5mg/ml).
Identity Determined by MS.
Other Product Data

Water Content (by Karl Fischer): ≤15%

Sodium Content: ≤2%

Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Keep cool and dry.
Use/Stability Stable for at least 1 year after receipt when stored at -20°C.
MSDS Inquire
Product Specification Sheet
Datasheet Download PDF
  • Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide inhibits human GCGR, GIPR and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively and mouse GCGR, GIPR, and GLP-1R with EC50 values of 2.32, 0.191 and 0.794 nM, respectively. It is an important tool for obesity research.
  • Retatrutide potently activates the GLP-1R signaling pathway to stimulate glucose-dependent insulin secretion through activity at the GIP receptor (GIPR) or the GLP-1R.
  • Retatrutide is a synthetic peptide with glucose-lowering effects. It is an antidiabetic agent against type 2 diabetes (T2D), stimulating insulin and suppressing glucagon secretion in a glucose-dependent manner.
  • Retatrutide was also shown to delay gastric emptying, lower fasting and postprandial glucose concentration, decrease food intake and reduce body weight in patients with type 2 diabetes.
Product References
  1. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept: T. Coskun, et al.; Cell Metab. 34, 1234 (2022)
  2. The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying: S. Urva, et al.; Diabetes Obes. Metab. 25, 2784 (2023)
  3. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial: S. Urva, et al.; Lancet 400, 1869 (2022)
  4. Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity? S.A. Doggrell; Expert Opin. Investig. Drugs 32, 355 (2023)
  5. Differentiation of human subcutaneous adipocytes and measurement of lipolytic function induced by GIP or LY3437943: A. Regmi & W. Roell; STAR Protoc. 4, 102304 (2023)
  6. Gut hormone co-agonists for the treatment of obesity: from bench to bedside: R. Nogueiras, et al.; Nature Metab. 5, 933 (2023) (Review)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.